Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy

Citation:
Greish, K., A. Ray, H. Bauer, N. Larson, A. Malugin, D. Pike, M. Haider, and H. Ghandehari, "Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy", Journal of Controlled Release, vol. 151, issue 3, pp. 263–270, 2011.

Abstract:

Tumor progression is dependent on neoangiogenesis for blood supply. Neovasculature over-express ?v?3 integrins which recognize the Arg-Gly-Asp (RGD) sequence in the extracellularmatrix.N-(2-hydroxypropyl) methacrylamide (HPMA) copolymers containing side chains terminated in cyclic RGD analogs such as RGDfK show increased accumulation in prostate tumors. Geldanamycin and their derivatives (e.g., aminohexylgeldanamycin (AH-GDM)) are benzoquinone ansamycins that have both antiangiogenic and antitumor activity. In this work the antiangiogenic and antitumor activities of targetable HPMA copolymer-RGDfK-AH-GDM conjugates were compared with nontargetable systems in vitro and in vivo. Copolymer-drug conjugates containing RGDfK in the side chains showed superior activity against endothelial and prostate cancer cell lines in vitro, aswell as higher inhibition of angiogenesis in vivo. At equimolar doses of the drug, the RGDfK containing conjugates showed significantly higher antitumor activity in nude mice bearing DU-145 human prostate cancer xenografts. These findings suggest the utility of HPMA copolymer-RGDfK conjugates for targeted delivery of geldanamycin analogs with a dual mode of action.

Notes:

n/a

PreviewAttachmentSize
CU-PDF907.58 KB